Abstract T P100: Optimal Duration of Dual Antiplatelet Therapy for Symptomatic Intracranial Stenosis

BACKGROUND: There is limited data on the optimal duration of dual antiplatelet therapy in combination with aggressive optimization of risk factors for secondary stroke prevention in patients with symptomatic intracranial stenosis. METHODS: Consecutive patients presenting to Emory University Hospital with high-grade (70-99%) symptomatic intracranial stenosis from January 1, 2011 to December 31, 2013 and evaluated within 30 days of the index event (stroke or TIA) were eligible for this analysis. All patients underwent treatment with aspirin plus clopidogrel for a target duration of 12 months along with aggressive medical management based on the SAMMPRIS protocol; all patients were given an H2 blocker as gastrointestinal prophylaxis for the duration of their aspirin and clopidogrel treatment. Clinical and safety outcomes of our cohort were compared with the medical arm of the SAMMPRIS trial cohort (n=227). RESULTS: Of 25 patients who met inclusion criteria, mean age was 65 +/- 14 years, 77% male, 58% white, ...